This short card is being folded into the full guide, which carries the dated trial and guideline sources: read the full evidence guide.
NMN
Also known as: Nicotinamide Mononucleotide · Beta-NMN
Raises blood NAD+ in small human trials (250 to 900 mg/day). Functional benefits so far are small or nominal, and trials are short.
Mechanism of Action
NMN is a precursor the body converts to NAD+, a coenzyme in cellular energy metabolism. Trials measure the rise in blood NAD+, not outcomes in tissues.
Doses and timing reported in studies
Context, not a recommendation. Study links for this card are still being added, so check the original trials and talk to your doctor before you take anything, especially with medicines or health conditions.
Range used in trials
250 mg/day (Igarashi 2022, Yoshino 2021); 300 to 900 mg/day (Yi 2023)
Timing used in trials
Not specified in the cited trials
Stacks Well With
Rubric
How evidence grades work
A grade summarises the strength of the human evidence for a compound or device category. It is not a score, it is not a rating of any brand, and it changes when new studies land.
- Strong
- Several randomised controlled trials or meta-analyses in people agree on direction, the effect is large enough to matter for the stated outcome, and safety is established over long use.
- Moderate
- Some human trials, but small, short, or mixed. Plausible benefit, with limited long-term safety data.
- Emerging
- Mostly animal or mechanism studies, or very small human studies. Interesting, not yet enough to act on.
- Weak
- Little or contradictory evidence, no benefit shown, or a safety concern outweighs the evidence.